3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colonic Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Rectal Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Interventions
Irinotecan
30
Gemcitabine
25
Paclitaxel
24
Cisplatin
24
Docetaxel
19
Oxaliplatin
15
Fluorouracil
15
alvocidib
13
Leucovorin
13
Carboplatin
12
Capecitabine
12
Bortezomib
10
Taxes
8
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
7
ixabepilone
6
Vorinostat
6
Topotecan
6
Temozolomide
6
Immunohistochemistry
6
Immunoenzyme Techniques
6
Bevacizumab
6
7-hydroxystaurosporine
6
tanespimycin
5
Sorafenib
5
Pharmacogenomic Testing
5
Pemetrexed
5
Etoposide
5
Chromatography, High Pressure Liquid
5
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
5
temsirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Unspecified Adult Solid Tumor, Protocol Specific
×
Resveratrol
×
Clear all
NCT00098969
2012-12-17
IRB 2004-535
National Cancer Institute (NCI)
Phase 1
Completed
40 enrolled